Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer

被引：3

作者：

Zhang, Dou ^{[1
,2
]}

Kong, Fanming ^{[1
,2
]}

Gao, Fangfang ^{[3
]}

Li, Longhui ^{[1
,2
]}

Liang, Yangyueying ^{[1
,2
]}

Yu, Minghui ^{[1
,2
]}

Zhao, Lu ^{[1
,2
]}

Wang, Na ^{[1
,2
]}

Jia, Yingjie ^{[1
,2
]}

机构：

[1] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Oncol, Anshanxi Rd, Tianjin 300193, Peoples R China

[2] Natl Clin Res Ctr Chinese Med Acupuncture & Moxibu, Tianjin, Peoples R China

[3] Tianjin Med Univ, Gen Hosp, Dept Pediat, Anshan Rd, Tianjin 300052, Peoples R China

来源：

HELIYON | 2024年 / 10卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Camrelizumab; Small-cell lung cancer; Chemotherapy; PD-L1; MULTICENTER; SURVIVAL; THERAPY; SAFETY;

D O I：

10.1016/j.heliyon.2023.e22913

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Objective: Exploring the clinical efficacy of camrelizumab in combination with first-line chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC). Methods: The clinical data of 35 patients with ES-SCLC who received camrelizumab combined with EC or EP regimen in First Teaching Hospital of Tianjin University of Traditional Chinese Medicine from January 2020 to January 2023 were retrospectively analyzed. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were OS, ORR and DCR. SPSS 25.0 software was used for statistical analysis, Kaplan-Meier curve and Log-Rank test analysis, and survival curve was drawn. Results: The median PFS of 35 patients with SCLC was 7.4 months (95 % CI 6.75-9.81 months), . and the median OS was 12.5 months (95% CI,11.71-16.90 months). The ORR and DCR were 65.7 % and 74.3 %, respectively. Adverse events (AEs) were mainly concentrated in grade 1-2, and the probability of occurrence of grade 3 or above was low. Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) was the most common, followed by nausea &vomit and anemia. The other common AEs included abnormal thyroid function, decreased neutrophil count, skin rash and leucopenia. Conclusion: Camrelizumab in combination with first-line chemotherapy regimens prolonged OS and PFS in SCLC patients and showed efficacy and safety in real-world data.

引用

页数：7

共 27 条

[1] Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China [J].

Chen, Ting ;

Xie, Ruixiang ;

Zhao, Qiuling ;

Cai, Hongfu ;

Yang, Lin .

FRONTIERS IN ONCOLOGY, 2022, 12

[2] Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer The ASTRUM-005 Randomized Clinical Trial [J].

Cheng, Ying ;

Han, Liang ;

Wu, Lin ;

Chen, Jun ;

Sun, Hongmei ;

Wen, Guilan ;

Ji, Yinghua ;

Dvorkin, Mikhail ;

Shi, Jianhua ;

Pan, Zhijie ;

Shi, Jinsheng ;

Wang, Xicheng ;

Bai, Yuansong ;

Melkadze, Tamar ;

Pan, Yueyin ;

Min, Xuhong ;

Viguro, Maksym ;

Li, Xingya ;

Zhao, Yanqiu ;

Yang, Junquan ;

Makharadze, Tamta ;

Arkania, Ekaterine ;

Kang, Wenying ;

Wang, Qingyu ;

Zhu, Jun .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (12) :1223-1232

[3] Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis [J].

Duan, Jianchun ;

Cui, Longgang ;

Zhao, Xiaochen ;

Bai, Hua ;

Cai, Shangli ;

Wang, Guoqiang ;

Zhao, Zhengyi ;

Zhao, Jing ;

Chen, Shiqing ;

Song, Jia ;

Qi, Chuang ;

Wang, Qing ;

Huang, Mengli ;

Zhang, Yuzi ;

Huang, Depei ;

Bai, Yuezong ;

Sun, Feng ;

Lee, J. Jack ;

Wang, Zhijie ;

Wang, Jie .

JAMA ONCOLOGY, 2020, 6 (03) :375-384

[4] Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial [J].

Fan, Yun ;

Zhao, Jun ;

Wang, Qiming ;

Huang, Dingzhi ;

Li, Xingya ;

Chen, Jianhua ;

Fang, Yong ;

Duan, Jianchun ;

Zhou, Caicun ;

Hu, Yanping ;

Yang, Haihua ;

Hu, Yi ;

Zhou, Jianying ;

Lin, Xiaoyan ;

Wang, Lifeng ;

Wang, Zhijie ;

Xu, Yanjun ;

Zhang, Tao ;

Shi, Wei ;

Zou, Jianjun ;

Wang, Jie .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) :299-309

[5] Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials [J].

Fang, Wenfeng ;

Yang, Yunpeng ;

Ma, Yuxiang ;

Hong, Shaodong ;

Lin, Lizhu ;

He, Xiaohui ;

Xiong, Jianping ;

Li, Ping ;

Zhao, Hongyun ;

Huang, Yan ;

Zhang, Yang ;

Chen, Likun ;

Zhou, Ningning ;

Zhao, Yuanyuan ;

Hou, Xue ;

Yang, Qing ;

Zhang, Li .

LANCET ONCOLOGY, 2018, 19 (10) :1338-1350

[6] CASPIAN: A method to identify chromatin topological associated domains based on spatial density cluster q [J].

Gong, Haiyan ;

Yang, Yi ;

Zhang, Xiaotong ;

Li, Minghong ;

Zhang, Sichen ;

Chen, Yang .

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2022, 20 :4816-4824

[7] Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study [J].

Huang, Jing ;

Xu, Jianming ;

Chen, Yun ;

Zhuang, Wu ;

Zhang, Yiping ;

Chen, Zhendong ;

Chen, Jia ;

Zhang, Helong ;

Niu, Zuoxing ;

Fan, Qingxia ;

Lin, Lizhu ;

Gu, Kangsheng ;

Liu, Ying ;

Ba, Yi ;

Miao, Zhanhui ;

Jiang, Xiaodong ;

Zeng, Ming ;

Chen, Jianhua ;

Fu, Zhichao ;

Gan, Lu ;

Wang, Jun ;

Zhan, Xianbao ;

Liu, Tianshu ;

Li, Zhiping ;

Shen, Lin ;

Shu, Yongqian ;

Zhang, Tao ;

Yang, Qing ;

Zou, Jianjun .

LANCET ONCOLOGY, 2020, 21 (06) :832-842

[8] PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations [J].

Jiang, Yongshuai ;

Chen, Ming ;

Nie, Hong ;

Yuan, Yuanyang .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (05) :1111-1122

[9] ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis [J].

Liu, Hong ;

Kuang, Xinwei ;

Zhang, Yongchang ;

Ye, Youqiong ;

Li, Jialu ;

Liang, Long ;

Xie, Zuozhong ;

Weng, Liang ;

Guo, Jia ;

Li, Hui ;

Ma, Fangyu ;

Chen, Xiaodan ;

Zhao, Shuang ;

Su, Juan ;

Yang, Nong ;

Fang, Fang ;

Xie, Yang ;

Tao, Juan ;

Zhang, Jianglin ;

Chen, Mingliang ;

Peng, Cong ;

Sun, Lunquan ;

Zhang, Xin ;

Liu, Jing ;

Han, Leng ;

Xu, Xiaowei ;

Hung, Mien-Chie ;

Chen, Xiang .

CANCER CELL, 2020, 37 (03) :324-+

[10] Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) [J].

Liu, Stephen, V ;

Reck, Martin ;

Mansfield, Aaron S. ;

Mok, Tony ;

Scherpereel, Arnaud ;

Reinmuth, Niels ;

Garassino, Marina Chiara ;

Carpeno, Javier De Castro ;

Califano, Raffaele ;

Nishio, Makoto ;

Orlandi, Francisco ;

Alatorre-Alexander, Jorge ;

Leal, Ticiana ;

Cheng, Ying ;

Lee, Jong-Seok ;

Lam, Sivuonthanh ;

McCleland, Mark ;

Deng, Yu ;

Phan, See ;

Horn, Leora .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06) :619-+

← 1 2 3 →